[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,885
  • Shares Outstanding, K 31,375
  • Annual Sales, $ 90 K
  • Annual Income, $ -33,890 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta -0.06
  • Price/Sales 386.96
  • Price/Cash Flow N/A
  • Price/Book 15.12

Options Overview Details

View History
  • Implied Volatility 919.25% (+468.37%)
  • Historical Volatility 61.48%
  • IV Percentile 97%
  • IV Rank 80.71%
  • IV High 1,130.39% on 12/03/25
  • IV Low 36.03% on 03/17/26
  • Expected Move (DTE 11) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 50
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,470
  • Open Int (30-Day) 2,024
  • Expected Range 1.0800 to 1.0800

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 1
  • High Estimate $-0.20
  • Low Estimate $-0.20
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +1.89%
on 06/05/26
1.3800 -21.74%
on 05/11/26
-0.1800 (-14.29%)
since 05/05/26
3-Month
0.9520 +13.45%
on 03/31/26
1.5294 -29.38%
on 04/21/26
-0.1000 (-8.47%)
since 03/05/26
52-Week
0.9520 +13.45%
on 03/31/26
1.9454 -44.48%
on 06/10/25
-0.6100 (-36.09%)
since 06/05/25

Most Recent Stories

More News
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

NEW YORK , June 3, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on June 2, 2026,...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

NEW YORK , June 3, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on June 2, 2026,...

ATNM : 1.0800 (-2.70%)
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

NEW YORK , June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

NEW YORK , June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on May 31, 2026...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

NEW YORK , May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

NEW YORK , May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutated models supporting its development as a mutation-agnostic therapy in settings where resistance to EGFR- and KRAS-targeted...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

NEW YORK , April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.0800 (-2.70%)
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

NEW YORK , April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted...

ATNM : 1.0800 (-2.70%)
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

NEW YORK , April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.0800 (-2.70%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 1.2067
2nd Resistance Point 1.1733
1st Resistance Point 1.1267
Last Price 1.0800
1st Support Level 1.0467
2nd Support Level 1.0133
3rd Support Level 0.9667

See More

52-Week High 1.9454
Fibonacci 61.8% 1.5659
Fibonacci 50% 1.4487
Fibonacci 38.2% 1.3315
Last Price 1.0800
52-Week Low 0.9520

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.